Biotechnology
Antengene Announces NDA Approval by NMPA for XPOVIO®, China's First XPO1 inhibitor, for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma
SHANGHAI and HONG KONG, Dec. 17, 2021 /PRNewswire/ -- Antengene Corporation Limited (the "Company" or "Antengene") is pleased to announce thatATG-010 (selinexor, brand name:XPOVIO®), a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound has received conditional approval for...
2021-12-17 22:27
6315
Westlake Omics Authorized as the Exclusive Distributor and Service Provider of Pressure BioSciences, Inc. in China
HANGZHOU, China, Dec. 17, 2021 /PRNewswire/ -- The Agreement signed by Westlake Omics (Hangzhou) Biotechnology Co., Ltd (hereinafter referred to as Westlake Omics) and Pressure BioSciences, Inc. (hereinafter referred to as PBI) on December 3, 2021 authorized Westlake Omics as the exclusive distrib...
2021-12-17 19:00
2421
Transcenta Announces the Appointment of Daniel Weng as CFO
SUZHOU, China, Dec. 17, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the appointment of Da...
2021-12-17 08:30
4852
Global Cord Blood Corporation Announces Rejection of Alternate Ocean Proposal
HONG KONG, Dec. 17, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that its Board of Directors (the "...
2021-12-17 05:16
4449
Gracell Biotechnologies Selected for Addition to NASDAQ Biotechnology Index
SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Dec. 16, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment o...
2021-12-16 21:00
3392
Bionomics Limited Announces Pricing of Initial Public Offering in the United States
ADELAIDE, Australia, Dec. 16, 2021 /PRNewswire/ -- Bionomics Limited (Bionomics orCompany), a clinical-stage biopharmaceutical company, today announced the pricing of its initial public offering inthe United States (the Offering) of 1,622,000 American Depositary Shares (ADSs), each representing 1...
2021-12-16 19:00
3503
Antengene and XtalPi Announce AI-Driven R&D Collaboration
SHANGHAI and HONG KONG, Dec. 16, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer and other life...
2021-12-16 16:30
4522
BioWorld by Clarivate Identifies the Top Six Global Biopharmaceutical Stories and Trends of 2021
Advances in Alzheimer's, innovation in DNA vaccines, increased regulatory collaboration and the evolving impact of Artificial Intelligence, join Covid-19 as key stories and trends of 2021 LONDON, Dec. 16, 2021 /PRNewswire/ -- BioWorld published by Clarivate Plc (NYSE:CLVT), a global leader in pr...
2021-12-16 16:14
2944
Debiopharm Further Explores the Potential of its Potent, Highly Selective WEE1 Inhibitor Debio 0123 In Phase 1 Cancer Study
Dose escalation, monotherapy trial launched to access the safety and
preliminary anti-tumor activity of Debio 0123 in the treatment of advanced
solid tumors
LAUSANNE, Switzerland, Dec. 16, 2021 /PRNewswire/ -- Debiopharm (
www.debiopharm.com
2021-12-16 16:00
2678
Novavax Announces Submission of New Drug Application in Japan for Approval of COVID-19 Vaccine
-- Takeda submits application for TAK-019/NVX-CoV2373, the first protein-based COVID-19 vaccine candidate for NDA, toJapan's Ministry of Health, Labour and Welfare (MHLW) -- Interim data from Phase 1/2 trial in Japan demonstrate robust immune response and favorable tolerability with no serious a...
2021-12-16 12:03
3441
Menarini Silicon Biosystems announces new DEPArray™ PLUS application to identify mutations in FFPE tissue samples with low tumor cellularity
Tissue biopsies with tumor cell contents that are too low for conventional testing methods can now be rescued due to the ability of MSB's DEPArray technology* to successfully recover low numbers of tumor cells from these difficult samples. The new FFPE Rescue Application* will provide patholog...
2021-12-16 08:30
2992
Statement by WuXi AppTec Regarding Recent Market Fluctuation
SHANGHAI, Dec. 15, 2021 /PRNewswire/ -- Our company's activities continue apace and we remain confident in our platform, which enables our global customers and serves patients around the world. We will provide any new information as warranted and in compliance with applicable laws and regulations...
2021-12-16 08:00
3226
AUSTRALIAN LIFE SCIENCE COMPANY, QBIOTICS, LAUNCHES STELFONTA® ITS LEAD VETERINARY PHARMACEUTICAL IN AUSTRALIA, FOLLOWING LAUNCHES IN OTHER KEY GLOBAL MARKETS
* QBiotics commences the Australian commercial launch of its lead veterinary drug, STELFONTA®, which is approved by the Australian Pesticides and Veterinary Medicines Authority (APVMA) for the treatment of canine non-metastatic mast cell tumours (MCT) * The Australian launch is a significant ...
2021-12-16 03:58
3560
FDA Breakthrough Devices Designation Application to Fast-Track Painful Finger-Prick Alternative for People Living with Diabetes
SYDNEY, Dec. 15, 2021 /PRNewswire/ -- Life Science Biosensor Diagnostics Pty Ltd (LSBD), a life sciences and medical technology company and subsidiary of The iQ Group Global, announced it has filed an application with the U.S Food and Drug Administration (FDA) for Breakthrough Devices Designation...
2021-12-15 21:01
2689
JW Therapeutics Presents Primary Clinical Response on Carteyva(R) (relmacabtagene autoleucel injection) in Adults with Relapsed/Refractory Follicular Lymphoma in China at the 63rd ASH Annual Meeting
SHANGHAI, Dec. 15, 2021 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, presented the primary clinical response on Carteyva® (relmacabtagene autoleucel injection) in...
2021-12-15 10:37
4805
RemeGen Reiterates Commitment to Its Battle Against Autoimmune Disease on World Strengthened Immunity Day 2021
YANTAI, China, Dec. 15, 2021 /PRNewswire/ -- To celebrate World Strengthened Immunity Day, RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, reiterated its commitment to discovering, developing, and producing best-in-class biological drugs for autoimmune diseases, to create c...
2021-12-15 09:35
4208
GenScript Receives "COVID Management Initiative of the Year" in Singapore Business Review Management Excellence Award 2021
SINGAPORE, Dec. 15, 2021 /PRNewswire/ -- GenScript receives the award on COVID Management Initiative of the Year, Biotechnology industry in the Singapore Business Review (SBR) Management Excellence Award 2021. GenScript showed strong commitment and support to global COVID-19 management including ...
2021-12-15 09:26
8018
ASH 2021 | Ascentage Pharma Releases Long-Term Clinical Data of Olverembatinib (HQP1351) in Oral Presentation Demonstrating Efficacy and Safety
SUZHOU, China, and ROCKVILLE, Md., Dec. 14, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released the updated data from three ...
2021-12-14 22:04
3221
CellCarta acquires Biogazelle to strengthen its genomic capabilities and expand into digital PCR (dPCR) services
This acquisition solidifies CellCarta's leadership position in genomic services with a unique combination of assay development and global clinical trial sample analysis capabilities covering a comprehensive range of established and cutting-edge genomic technologies. MONTREAL, Dec. 14, 2021 /PRNe...
2021-12-14 20:25
5102
Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial
MELBOURNE, Australia, Dec. 14, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that the New Zealand Medicines and Medic...
2021-12-14 20:25
2632
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 273 media titles]
2026-10-09 13:21The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24